ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder (MDD)

November 7, 2022

https://www.globenewswire.com/news-release/2022/11/07/2549739/0/en/ABVC-BioPharma-Receives-Notice-of-Allowance-from-US-Patent-and-Trademark-Office-for-ABV-1504-Used-to-Treat-Major-Depressive-Disorder-MDD.html

FREMONT, CA, Nov. 07, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ:ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that on October 20, 2022, it received a Notice of Allowance for ABV-1504 from the US Patent and Trademark Office.

Read more at globenewswire.com

Related news for (ABVC)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.